Contract Research Organization (CRO) Business Valuation
Who this is for
CRO founders evaluating PE investment or strategic acquisition, pharma corporate development teams assessing CRO partnerships, and life sciences investors benchmarking portfolio CRO assets.
What drives value in CRO Services
- Backlog size and book-to-bill ratio as a revenue visibility indicator
- Therapeutic area specialization (oncology, rare disease) commanding premium rates
- Regulatory track record and FDA-facing submission experience
- Site network breadth and patient recruitment capability
- Repeat sponsor relationships and preferred vendor agreements
- Revenue per scientific FTE as a productivity benchmark
Valuation methods we use
CROs are valued at 8–15× EBITDA, with premiums for oncology specialization, large backlog coverage, and preferred sponsor relationships. Revenue multiples (1–3×) and backlog multiples provide secondary validation. This tool is informational only. Output is driven by your inputs and does not constitute a formal appraisal or certified valuation.
Typical metrics and inputs
Backlog
Total contracted future revenue not yet recognized; typically 12–24 months of forward revenue for well-positioned CROs.
Book-to-bill ratio
New awards divided by revenue recognized in the period; >1.0× signals growth; <0.9× signals contraction.
Revenue per FTE
Annual revenue divided by total headcount; benchmark is $120K–$250K for mid-size CROs.
EBITDA margin
Typically 12–22% for specialized CROs after R&D labor and overhead.
Repeat sponsor revenue %
Revenue from sponsors who awarded work in the prior year; high repeat rates indicate quality delivery.
Example scenarios
Oncology-focused Phase 1-2 CRO
A specialized oncology CRO with $20 M revenue, $30 M backlog, and 18% EBITDA might be valued at 10–13× EBITDA by a strategic pharma acquirer.
General-purpose mid-size CRO
A broad-spectrum CRO with $40 M revenue, diversified therapeutic areas, and 15% EBITDA margins might trade at 8–10× EBITDA.
Frequently asked questions
What multiple does a CRO sell for?
Specialized CROs trade at 10–15× EBITDA; general-purpose mid-size CROs at 7–10×. Strategic acquirers may pay higher for capability or geographic access.
How important is backlog in CRO valuation?
Critical — backlog provides revenue visibility and de-risks projections. Buyers typically want 12+ months of backlog coverage before paying a full multiple.
Does FDA experience add to CRO value?
Yes — CROs with a track record of successful NDA/BLA submissions command premium rates and multiples due to regulatory risk mitigation for sponsors.
How does therapeutic area specialization affect CRO valuation?
Oncology and rare disease specialists earn higher per-patient and per-study revenues, command stronger repeat business, and attract strategic acquirer premiums.
Is this a certified appraisal?
No. This tool provides informational estimates. For formal CRO M&A, engage a life sciences M&A advisor.
Run your CRO Services valuation
Get a professional-grade valuation report using DCF, comparable companies, precedent transactions, and scenario analysis — for just $9.99.
Join the waitlist →Related industries
Biotech & Pharma
Value a biotech or pharmaceutical company using rNPV, pipeline analysis, and pharma comparable transactions. AI-powered reports for $9.99.
Healthcare Services
Value a healthcare services company using EBITDA multiples, revenue per provider, and payer mix analysis. AI-powered reports for $9.99.
Professional Services
Value a consulting, accounting, legal, or advisory firm using EBITDA multiples, revenue per professional, and client retention analysis. Reports for $9.99.
Staffing
Value a staffing or recruiting agency using gross profit multiples, EBITDA, and fill-rate benchmarks. AI-powered reports for $9.99.